Th1 cytokine-based immunotherapy for cancer.

@article{Xu2014Th1CI,
  title={Th1 cytokine-based immunotherapy for cancer.},
  author={Hong-mei Xu},
  journal={Hepatobiliary & pancreatic diseases international : HBPD INT},
  year={2014},
  volume={13 5},
  pages={
          482-94
        }
}
Cytokine-based immunotherapy is executed by harnessing cytokines to activate the immune system to suppress tumors. Th1-type cytokines including IL-1, IL-2, IL-12 and granulocyte-macrophage colony-stimulating factor are potent stimulators of Th1 differentiation and Th1-based antitumor response. Many preclinical studies demonstrated the antitumor effects of Th1 cytokines but their clinical efficacy is limited. Multiple factors influence the efficacy of immunotherapy for tumors. For instance… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

A novel antigen delivery system induces strong humoral and CTL immune responses.

  • Biomaterials
  • 2017
VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Novel insights into the role of aptamers in the fight against cancer

  • Journal of Cancer Research and Clinical Oncology
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation

  • Clinical and translational radiation oncology
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

Curcumin up regulates T helper 1 cells in patients with colon cancer.

  • American journal of translational research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

IL-17 promoted the inhibition of medulloblastoma in mice by splenocyte injection

  • European Journal of Medical Research
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers